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A ‘cocktail’ consisting of an inhibitor of diacylglycerol kinase (R59022, 10 PM), an inhibitor of diacylglycerol lipase 
(RHC80267, IO PM), and an inhibitor of phospholipase A, (either 100 PM indomethacin, or 100 PM sodium meclofenam- 
ate) markedly enhanced superoxide production by human neutrophils stimulated with post-receptor stimuli, fluoride and 
y-hexachlorocyclohexane. On the other hand, the response to the C3b/Fc receptor stimulus, opsonized zymosan, was 
marginally decreased whilst that to the Fc receptor stimulus, aggregated IgG, was virtually unaffected. Since the inhibitors 
used are deemed to inhibit the main routes of arachidonate production, these results call into question the role of arachi- 
donate in the transduction of 0; generation by post-receptor stimuli, but support a role for arachidonate in receptor- 
mediated transduction. 
Neutrophil; Superoxide; Diglyceride kinase; Diglyceride lipase: Arachidonate: Protein kinase C 
1. INTRODUCTION 
The pathways involved in the signal- 
transduction of the respiratory burst in the 
neutrophil are far from clear. It has been proposed 
that stimulus-activation coupling in many cell 
types involves the breakdown of phosphatidyl- 
inositol bisphosphate (PIP2) to give inositol tris- 
phosphate (which increases intracellular Ca2 ’ ) and 
diacylglycerol (DAG) (which activates protein 
kinase C) and that the two pathways function 
synergistically [1,2]. Evicence has been put for- 
ward which suggests that synergistic interaction 
between these two pathways could participate in 
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signal transduction for the neutrophil respiratory 
burst [3-61. However there is controversy over 
whether protein kinase C really is implicated in 
receptor-mediated 0; production: there are some 
data indicating that it is not involved [7,8] and 
some that it is [9,10]. There is evidence that oleoyl 
acetylglycerol (OAG) (and by implication, DAG) 
can invoke transduction mechanisms for the ox- 
idative burst which do not involve protein kinase C 
[l I] and other evidence for a receptor-mediated 
burst which is PIP2 independent but which does in- 
volve protein kinase C [ 12,131. In this latter case it 
could be of importance that DAG can be derived 
from phosphatidylcholine [14]. 
Several observations suggest that arachidonate 
or its metabolites could be involved in stimulus- 
activation coupling for the respiratory burst. Thus 
exogenous arachidonate can activate NADPH- 
oxidase in intact neutrophils [15] and in a cell-free 
preparation of neutrophil cytosol and membrane 
components (discussed in [ 161). However, whether 
endogenously released arachidonate is implicated 
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in neutrophil transduction mechanisms is still an 
open question, though participation of 
arachidonate has been suggested [l l] and lipoxins 
derived from arachidonate are reported to activate 
protein kinase C [17]. 
The main potential sources of arachidonate are 
deemed to be from phosphatidylcholine, phos- 
phatidylethanolamine or phosphatidic acid (PA) 
by phospholipase AZ action, or from the 
phosphoinositides by sequential action of phos- 
pholipase C and DAG lipase (see [18] for review). 
It is possible to inhibit all these pathways 
simultaneously. DAG lipase can be inhibited by 
RHC80267 [19] and the generation of PA from 
DAG by DAG kinase can be inhibited by R59022 
[20]. Indeed we recently reported results with these 
two compounds on the neutrophil respiratory 
burst [21], results which have since been confirmed 
[22,23]. It has also been demonstrated that 
neutrophil phospholipase AZ can be inhibited by 
indomethacin [24] and by meclofenamate [25]. A 
combination of either of these latter two com- 
pounds with the inhibitor of DAG lipase plus the 
inhibitor of DAG kinase should prevent release of 
arachidonate from all the sources specified above. 
In the present study we have examined the effect 
of this inhibitory cocktail on superoxide release 
produced by both receptor and non-receptor 
stimuli, in order to obtain some information as to 
whether endogenous arachidonate is involved in 
the transduction of the oxidative burst. The recep- 
tor stimuli used were opsonized zymosan and ag- 
gregated IgG, and the post-receptor stimuli were 
fluoride [26], which acts, at least in part, via the G- 
protein coupled to phospholipase C [27] and y- 
hexachlorocyclohexane (y-HCCH). This latter 
agent is known to activate the oxidative burst [28]. 
It can cause PIP2 breakdown but there is evidence 
that its action involves perturbation of membrane 
phospholipids [29], rendering them more accessi- 
ble for degradation. Its mechanism of action thus 
implies the potential mobilization of arachidonate 
from several phospholipid sources. In this connec- 
tion it is significant that lipocortin, which quite 
clearly can prevent the release of arachidonate and 
its metabolites [30], has not only been shown to in- 
hibit phospholipase A2 by sequestering its 
phospholipid substrates [31] but to manifest 
calcium-dependent binding to phosphatidylserine 
liposomes [32]. 
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2. MATERIALS AND METHODS 
Blood was collected from human volunteers by venipuncture 
and neutrophils prepared by Ficoll-lsopaque separation as 
described [21]. The cells were subsequently suspended in the ap- 
propriate buffer. For opsonized zymosan, IgG and r-HCCH, a 
Ca’+-free Tyrode solution was employed, containing 137 mM 
NaCI, 2.7 mM KCI, 1 mM MgC12, 1 mg/ml glucose, 1 mg/ml 
bovine serum albumin and buffered with 20 mM (Hepes) at pH 
7.4. A modified Dulbecco’s phosphate buffered saline (PBS) 
was used for all fluoride experiments: a Ca2+ and Mg’+ free 
solution containing 136.9 mM NaCI, 2.7 mM KCI, 8.1 mM 
NazHPO.+, 1.5 mM KHzPOd in which the concentration of 
NaCl was reduced so that the final salt concentration was 
physiological after the addition of NaF. 
Zymosan was opsonized with autologous serum as previously 
described [21] and suspended in Ca’+-free Tyrode solution to 
give a final concentration of 1 mg/ml. IgG (human) was 
suspended at 2.5 mg/ml in Ca 2+-free Tyrode solution. Heat- 
aggregated IgG was produced by heating the IgG for 15 min at 
63°C. 
The neutrophils suspended at 4 x lo6 cells/ml were 
equilibrated for 20 min at 37”C, the appropriate concentration 
of drug then added and allowed a further 20 min preincubation. 
Into the assay tubes was dispensed 1 mg ferricytochrome c 
(horse heart type III), plus either the particular stimulus at the 
appropriate dilution, or Tyrode, and also either 75 units 
superoxide dismutase or Tyrode. The final Ca’+ concentration 
was 3 mM, except in fluoride experiments where it was 0.31 
mM, to avoid precipitation of CaF2. 
The reaction was initiated by the addition of 2 x lo6 cells to 
the assay tubes, and incubation continued at 37°C for 100 min 
for IgG stimulus, or 30 min for all other stimuli, the reaction 
being stopped by the addition of 1 mM N-ethylmaleimide. 
Following centrifugation at 1400 x g for 10 min at 4”C, the ab- 
sorbance of the supernatant was read at 550 nm in a Beckman 
DU-50 spectrophotometer. The amount of Or produced was 
calculated by dividing the difference in absorbance of the 
samples, with and without superoxide dismutase, by the extinc- 
tion coefficient for the change between ferricytochrome c and 
ferrocytochrome c (&SO = 15.5 mM-’ cm-‘) and the resulting 
value converted to nmolO2 produced. Results are expressed as 
% mean maximum 02 produced by the stimulus alone. 
R59022 was obtained from Janssen Pharmaceutical 
(England), sodium meclofenamate from Parke Davis 
(England), all other reagents were from Sigma and 
RHC80267-2 was a generous gift from Dr A. Khandwala of 
Revlon Health Care Group (USA). 
3. RESULTS 
A combination of the DAG kinase inhibitor, 
R59022 at 10 PM, the DAG lipase inhibitor, 
RHC80267 at lOpM, and indomethacin at lOOpM, 
markedly shifted the concentration-response curve 
to fluoride to the left. The mean maximum was 
also increased with the drug combination (fig.lA). 
Similar results were obtained when meclofenamate 
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Fig. 1. Potentiation of fluoride-induced 02 generation by a combination of inhibitors of arachidonate production. Results are express- 
ed as % mean maximum 02 with fluoride alone (15.5 nmol per lo6 cells in A; 20.7 nmol per lo6 cells in B). Fluoride concentration 
is expressed on a log scale. (0) Fluoride alone; (m) with a combination of the DAG kinase inhibitor, R59022 (IOpM), the DAG lipase 
inhibitor, RHC80267 (IOpM), and a phospholipase inhibitor which was indomethacin (100 PM) in A (n = 5) and meclofenamate (100 
PM) in B (n=3). All data points represent mean k SE. 
was substituted for indomethacin (fig.lB). The 
same two cocktails of reagents caused marked left- 
shifts in the concentration-response curves to y- 
HCCH. The meclofenamate-containing cocktail 
also increased the mean maximum response 
(fig.2A,B). 
When used with receptor stimuli, the combina- 
tion of drugs RHC80267, R59022 and sodium 
meclofenamate produced the opposite effect. In 4 
experiments there was always a consistent right 
0.01 0.1 1 0.01 0.1 1 
HCCH (mM) HCCH (mM) 
shift in the concentration-response curve to op- 
sonized zymosan (fig.3). All data points in figs.l,2 
and 3 represent mean f SE; at some points the er- 
rors are too small to appear. The meclofenamate- 
containing cocktail also inhibited IgG-stimulated 
0; release by 26 f 11.8% (mean f SE, n = 3) 
but had no significant effect on heat aggregated 
IgG-mediated superoxide release (6 + 7.9% in- 
hibition, n = 3). 
In 7-experiments odium meclofenamate (100 
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Fig.2. Potentiation of y-HCCH-induced 02 generation by a combination of inhibitors of arachidonate production. Results are ex- 
pressed as % mean maximum 02 produced by y-HCCH alone (27.4 nmol per IO6 cells in A; 29.2 nmol per lo6 cells in B). (0) y- 
HCCH alone; (B) with a combination of the DAG kinase inhibitor, R59022 (IOpM), the DAG lipase inhibitor, RHC80267 (lOaM), 
and a phospholipase inhibitor which was.indomethacin (lOOaM) in A (n = 3) and meclofenamate (IOOrM) in B (n = 3). All data points 
represent mean + SE. 
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Fig.3. The effect of a combination of inhibitors of arachidonate 
production on opsonized zymosan-stimulated 02 production. 
Results are expressed as per cent of the maximum Oi produced 
by opsonized zymosan alone (26.8 nmol per lo6 cells). (0) Op- 
sonized zymosan alone; (w) with a combination of the DAG 
kinase inhibitor, R59022 (10 pM), the DAG lipase inhibitor, 
RHC80267 (10 FM), and sodium meclofenamate (100 ,uM). All 
data points represent mean f SE (n = 4). 
PM) used on its own with these receptor stimulants 
did not decrease superoxide production (not 
shown) and we have previously reported that when 
R59022 and RHC80267 were used on their own the 
former enhanced and the latter had no effect on 
receptor-mediated superoxide production [21]. 
4. DISCUSSION 
Indomethacin and meclofenamate were de- 
scribed quite independently by two separate groups 
as being inhibitors of phospholipase A2 [24,25]. In 
the present study, remarkably similar results were 
obtained with post-receptor stimuli when either of 
these was added to the combination of R59022 plus 
RHC80267. In experiments with receptor stimuli, 
only meclofenamate was used in the cocktail since, 
in a rigorous experimental study, indomethacin 
has been described as competitively inhibiting the 
binding and neutrophil activation of some receptor 
ligands [33,34]. 
In considering the problem of signal transduc- 
tion for the respiratory burst in the neutrophil, a 
role for arachidonate seems to be implied in both 
the study whose data indicate that respiratory 
burst transduction can involve PIP2 turnover but 
not protein kinase C activity [ll], and the study 
whose data indicate that it can involve protein 
kinase C activity but not PIP2 turnover [12,13]. 
Certainly exogenous arachidonate can activate 
NADPH oxidase [15,16]. The role of endogenous 
arachidonate in the transduction process is dif- 
ficult to investigate rigorously. Techniques involv- 
ing the use of radioactive arachidonate have 
several serious drawbacks (discussed in [18]). One 
major drawback is that several distinct pools of 
arachidonate exist and there may be continuous 
acylation and reacylation of the phospholipids in 
these pools, even in a ‘resting’ cell. Another is that 
reacylation of the key phospholipids which are 
transiently deacylated during cell activation may 
confuse the results, especially if cell activation is 
measured over periods up to 10 min or more. We 
have therefore chosen to address the question by 
measuring the effect of a mixture of agents which 
have been shown to inhibit the main pathways in- 
volved in arachidonate release. The results show 
that not only did the inhibitors fail to decrease 02 
generation by stimuli acting at non-receptor sites, 
but they actually increased it. However the cocktail 
of inhibitors marginally decreased receptor- 
stimulated 02 production. An interpretation of 
these results must take cognisance of the possibility 
that indomethacin, in addition to its known effects 
on cyclooxygenase and phospholipase AZ, may 
also be an inhibitor of DAG metabolism [35]. Tak- 
ing this possibility into account (and with the 
caveat that the inhibitors used could have actions 
other than the ones specified), one explanation for 
the increased 0; generation seen when these 
agents were used with post-receptor stimuli is that, 
since they could have inhibited DAG metabolism 
and increased DAG levels, the resultant increased 
protein kinase C activation could have more than 
compensated for the elimination of the putative 
arachidonate pathway(s). If this explanation is cor- 
rect, it emphasizes the importance of the protein 
kinase C pathway in the oxidative burst. 
There are several possible explanations for the 
fact that the mixture of inhibitors had a different 
effect on the receptor-mediated response from that 
seen with post-receptor stimuli, i.e. a marginal 
depression instead of enhancement. One is that the 
marked protein kinase C activation brought about 
by increased DAG levels could have had a negative 
feedback effect either by phosphorylation of the 
receptor, as happens with cur-adrenergic receptors 
[36] or by block of the coupling of the receptor to 
the G-protein(s) [37]. Another possible explana- 
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tion is that receptor-mediated generation of an en- 
dogenous inhibitor of protein kinase C such as 
sphingosine could have modulated the response 
[38]. However, a further possible explanation, and 
one that merits consideration, is that the oxidative 
burst which follows receptor-stimulation might, in 
addition to PIP2 degradation, require the activa- 
tion of another pathway (one which involves 
arachidonate) perhaps through phospholipase A2 
coupled to the receptor [39], the coupling possibly 
being by the G-protein reported to be involved 
with the PIPz-independent pathway [13]. If 
arachidonate generation were a necessary element 
in receptor-mediated 02 release, inhibition of 
such generation might well give the results obtain- 
ed in the present paper, since even very potent ac- 
tivation of the protein kinase C pathway would not 
then compensate for the elimination of this 
putative arachidonate pathway. A receptor- 
coupled arachidonate pathway could explain the 
results previously reported [12], i.e. that pretreat- 
ment of neutrophils with PMA resulted in virtual 
elimination of the subsequent FMLP-induced PIP2 
turnover but increased the concomitant 02 pro- 
duction. Support for the possibility that an 
arachidonate pathway could be implicated in the 
receptor-mediated oxidative burst has been provid- 
ed by a recent report that lipocortin, known to in- 
hibit the release of arachidonate and its 
metabolites, decreases receptor-mediated but not 
PMA-mediated Hz02 production [40]. 
Clearly the transduction pathways for the 
neutrophil respiratory burst are extremely complex 
and await clarification. 
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